- Upadacitinib and adalimumab reduced pain vs placebo in rheumatoid arthritis and psoriatic arthritis.
- In rheumatoid arthritis, upadacitinib provided greater early pain relief than adalimumab.
- In psoriatic arthritis, pain reductions were similar with upadacitinib and adalimumab.
- Pain improvement occurred even with residual inflammation.
- Analyses suggest both anti-inflammatory and direct pain-modulating effects.
Source: RMD Open
